[2-苯基-2-氧代乙基]氨基-2-氧代乙酸乙酯 | 84978-66-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: [2-苯基-2-氧代乙基]氨基-2-氧代乙酸乙酯
• 中文别名: 2-(2-氧代-2-苯乙基氨)乙酸乙酯
• 英文名称: ethyl 2-oxo-2-((2-oxo-2-phenylethyl)amino)acetate
• 英文别名: ethyl 2-oxo-2-(phenacylamino)acetate
• CAS: 84978-66-5
• 化学式: C₁₂H₁₃NO₄
• 分子量: 235.24
• InChiKey: FJIIFNUNDAWHGH-UHFFFAOYSA-N

物化性质

• 熔点：
  96-97 °C(Solv: water (7732-18-5))
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P260,P264,P273,P301+P312,P305+P351+P338,P314
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H319,H372,H410

反应信息

• 作为反应物：
  描述：

  [2-苯基-2-氧代乙基]氨基-2-氧代乙酸乙酯 在 三氯氧磷 作用下， 反应 3.5h， 以64%的产率得到5-苯基噁唑-2-羧酸乙酯
  参考文献：
  名称：

  异羟肟酸作为FeII和MnII的强抑制剂大肠杆菌蛋氨酸氨基肽酶：恶唑异羟肟酸酯-EcMetAP-Mn复合物的生物活性和X射线结构

  摘要：

  合成了与五元杂环（包括呋喃，恶唑，1,2,4或1,3,4-恶二唑和咪唑）连接的新系列酸和异羟肟酸，并测试了它们对Fe II，Co II和Fe的抑制剂。Mn II形式的大肠杆菌蛋氨酸氨肽酶（MetAP），并且是针对野生型和acrAB大肠杆菌菌株的抗菌剂。2-芳基恶唑-4-基羧酸似乎是Co II MetAP形式的有效抑制剂和选择性抑制剂，IC 50值在微摩尔范围内，而5-芳基恶唑-2-基羧酸区域异构体和5-芳基1,2,4恶二唑-3-基羧酸对所有形式的Ec均无效MetAP。无论杂环的，所有的异羟肟酸是高度有效的抑制剂和有选择性的锰II和Fe II的形式，用IC 50个1和2之间的值μ中号。我们之前报道过的一种吲哚异羟肟酸是大肠杆菌肽去甲酰基酶的有效抑制剂，也证明了它对Ec MetAP的有效性。为了深入了解在2和5位上具有反向取代的恶唑杂环的位置，Ec的X射线晶体结构解决了与两种此类恶唑异羟肟酸复合的MetAP-Mn。不管[金属]

  DOI：

  10.1002/cmdc.201200076
• 作为产物：
  描述：

  2-溴苯乙酮 在 吡啶 、 乌洛托品 作用下， 以 乙醇 为溶剂， 反应 27.0h， 生成 [2-苯基-2-氧代乙基]氨基-2-氧代乙酸乙酯
  参考文献：
  名称：

  Probing the ‘bipolar’ nature of the carbonic anhydrase active site: Aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms

  摘要：

  A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared via a direct, chemoselective sulfochlorination of a range of 1,3-oxazolyl benzenes and thiophenes, followed by primary sulfonamide synthesis. The latter functionality is a known zinc-binding group (ZBG) responsible for anchoring the inhibitors to the CA's zinc metal ion. The compound's periphery as well as the overall scaffold geometry was designed to enable optimal interactions with the two distinct sides of the enzyme's active site, one of which is lined with hydrophobic residues and while the other is predominantly hydrophilic. As a result, several compounds inhibiting the therapeutically important cytosolic CA I and CA II in picomolar range have been identified. These compounds are one of the most potent CA inhibitors identified to-date. Not only the remarkable (>10 000-fold), cytosolic CA I and CA II selectivity vs. the membrane-bound CA IX and CA XII isoforms, but also the pronounced CA II/I selectivity observed in some cases, allow considering this series as a set of isoform-selective chemical biology tools and promising starting points for drug candidate development. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.06.022

文献信息

• [EN] ANTIBACTERIAL BENZOIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES BENZOIQUES ANTIBACTERIENS
  申请人：UPJOHN CO

  公开号：WO2004018428A1

  公开（公告）日：2004-03-04

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗菌剂和使用这些剂进行哺乳动物的消毒、卫生、防腐、消毒和治疗感染的方法。
• [EN] Novel Compounds<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017103614A1

  公开（公告）日：2017-06-22

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

  本发明涉及新型化合物和制备去泛素酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C-末端水解酶30或泛素特异性肽酶30（USP30）。本发明进一步涉及在治疗涉及线粒体功能障碍和癌症的疾病中使用DUB抑制剂。本发明的化合物包括具有以下式（I）的化合物：（I）或其药用可接受盐，其中R1a、R1b、R1c、R1d、R1e、R1f、R1g、R2、X、L和A如本文所定义。
• FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR
  申请人：SUZHOU SINOVENT PHARMACEUTICALS CO., LTD.

  公开号：US20180271846A1

  公开（公告）日：2018-09-27

  The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

  本发明公开了一种五元杂环酰胺WNT通路抑制剂，属于调节Wnt信号通路活性的化合物，并提供了制备这种化合物的方法，以及在制备对抗Wnt信号通路的药物中使用这种化合物的用途。本发明提供的五元杂环酰胺WNT通路抑制剂基于靶向合理药物设计具有显著的抗肿瘤活性，可用于新一代Wnt通路抑制剂的开发，并具有巨大的临床应用价值和相当大的市场潜力。
• [EN] PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVATIFS DE PYRIDINESULFONAMIDE POUVANT ÊTRE UTILISÉS COMME MODULATEURS TRAP1 ET LEURS UTILISATIONS
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188907A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了化合物的化学式（I）和药学上可接受的盐、溶剂化合物、水合物、多晶型、共晶体、互变异构体、立体异构体、同位素标记化合物以及其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能恢复PTEN诱导的激酶1（"PINK1"）功能丧失情况下的活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，和/或减少活性氧自由基的产生。所提供的化合物还可能对聚集或错误折叠的蛋白质（如α-突触核蛋白）进行重折叠或溶解。本公开还提供了包括所提供化合物的药物组合物；包括所提供化合物或药物组合物的试剂盒；以及使用所提供的化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• [EN] URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE<br/>[FR] DÉRIVÉS D'URIDINE NUCLÉOSIDE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：UNIV TUFTS

  公开号：WO2018058148A1

  公开（公告）日：2018-03-29

  This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to compounds, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

  这项披露涉及尿苷核苷衍生物，包含治疗有效量的这些核苷衍生物的组合物，以及使用这些核苷衍生物或组合物治疗对P2Y6受体的化合物（如激动剂）具有反应的疾病的方法，例如神经疾病，包括神经退行性疾病（如阿尔茨海默病、帕金森病）和创伤性中枢神经系统损伤、疼痛、唐氏综合症（DS）、青光眼和炎症性疾病。